Velpatasvir (Synonyms: GS-5816)

Name: Velpatasvir
Brand: MedChemExpress
SKU: HY-12530
Rating: 5.0 (10 reviews)

Cat. No.: HY-12530 Purity: 99.17%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL^pro inhibitor with an IC₅₀ of 2.16 μM.

For research use only. We do not sell to patients.

Velpatasvir Chemical Structure

CAS No. : 1377049-84-7

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 66	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 66	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 38	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 60	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 140	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 200	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 10 publication(s) in Google Scholar

Other Forms of Velpatasvir:

Velpatasvir-d7 Get quote
Velpatasvir (Standard) Get quote

10 Publications Citing Use of MCE Velpatasvir

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2	CC₅₀	> 44400 nM Compound: 39; VEL, GS-5816	Cytotoxicity against human HepG2 cells infected with HCV genotype 1a H77 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay Cytotoxicity against human HepG2 cells infected with HCV genotype 1a H77 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay	[PMID: 31230974]
HepG2	CC₅₀	> 44400 nM Compound: 39; VEL, GS-5816	Cytotoxicity against human HepG2 cells infected with HCV genotype 1b Con-1 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay Cytotoxicity against human HepG2 cells infected with HCV genotype 1b Con-1 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay	[PMID: 31230974]
Huh-7	CC₅₀	> 44400 nM Compound: 39; VEL, GS-5816	Cytotoxicity against human HuH7 cells infected with HCV genotype 1a H77 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay Cytotoxicity against human HuH7 cells infected with HCV genotype 1a H77 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay	[PMID: 31230974]
Huh-7	CC₅₀	> 44400 nM Compound: 39; VEL, GS-5816	Cytotoxicity against human HuH7 cells infected with HCV genotype 1b Con-1 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay Cytotoxicity against human HuH7 cells infected with HCV genotype 1b Con-1 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay	[PMID: 31230974]
MRC5	CC₅₀	> 44400 nM Compound: 39; VEL, GS-5816	Cytotoxicity against human MRC5 cells infected with HCV genotype 1a H77 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay Cytotoxicity against human MRC5 cells infected with HCV genotype 1a H77 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay	[PMID: 31230974]
MRC5	CC₅₀	> 44400 nM Compound: 39; VEL, GS-5816	Cytotoxicity against human MRC5 cells infected with HCV genotype 1b Con-1 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay Cytotoxicity against human MRC5 cells infected with HCV genotype 1b Con-1 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay	[PMID: 31230974]
MT4	CC₅₀	> 44400 nM Compound: 39; VEL, GS-5816	Cytotoxicity against human MT4 cells infected with HCV genotype 1a H77 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay Cytotoxicity against human MT4 cells infected with HCV genotype 1a H77 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay	[PMID: 31230974]
MT4	CC₅₀	> 44400 nM Compound: 39; VEL, GS-5816	Cytotoxicity against human MT4 cells infected with HCV genotype 1b Con-1 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay Cytotoxicity against human MT4 cells infected with HCV genotype 1b Con-1 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay	[PMID: 31230974]
PC-3	CC₅₀	> 44400 nM Compound: 39; VEL, GS-5816	Cytotoxicity against human PC3 cells infected with HCV genotype 1a H77 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay Cytotoxicity against human PC3 cells infected with HCV genotype 1a H77 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay	[PMID: 31230974]
PC-3	CC₅₀	> 44400 nM Compound: 39; VEL, GS-5816	Cytotoxicity against human PC3 cells infected with HCV genotype 1b Con-1 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay Cytotoxicity against human PC3 cells infected with HCV genotype 1b Con-1 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay	[PMID: 31230974]

In Vivo

Velpatasvir (10 mg/kg/d, p.o.) alone or in combination with Sofosbuvir (HY-15005) (20 mg/kg/d) inhibits liver fibrosis in the CCl₄-induced non-HCV rat model^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CCl₄-induced non-HCV rat model^[3]
Dosage:	10 mg/kg/d alone, or in combination with Sofosbuvir (20 mg/kg/d)
Administration:	p.o.
Result:	Decreased the levels of TNF-a, NF-κB and IL-6 in serum and hepatic tissues. Inhibited hepatic stellate cells (HSCs).

Clinical Trial

Molecular Weight

883.00

Formula

C₄₉H₅₄N₈O₈

CAS No.

1377049-84-7

Appearance

Solid

Color

White to off-white

SMILES

O=C(N([C@H]1C)[C@@H](CC1)C2=NC3=C(C(C=C(OCC4=CC(C5=CN=C([C@H](C[C@H](COC)C6)N6C([C@@H](C7=CC=CC=C7)NC(OC)=O)=O)N5)=CC=C84)C8=C9)=C9C=C3)N2)[C@H](C(C)C)NC(OC)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (113.25 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.1325 mL	5.6625 mL	11.3250 mL
5 mM	0.2265 mL	1.1325 mL	2.2650 mL
10 mM	0.1133 mL	0.5663 mL	1.1325 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (2.83 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (2.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.26%

Select Batch:

Data Sheet (282 KB) SDS (252 KB)

COA (252 KB)

Handling Instructions (2659 KB)

References

[1]. Lawitz EJ et al. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5368-78. [Content Brief]

[2]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212. [Content Brief]

[3]. Yasmeen S, et al. An insight into the hepatoprotective role of Velpatasvir and Sofosbuvir per se and in combination against carbon tetrachloride-induced hepatic fibrosis in rats. Environ Sci Pollut Res Int. 2023 Sep;30(42):95660-95672. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.1325 mL	5.6625 mL	11.3250 mL	28.3126 mL
	5 mM	0.2265 mL	1.1325 mL	2.2650 mL	5.6625 mL
	10 mM	0.1133 mL	0.5663 mL	1.1325 mL	2.8313 mL
	15 mM	0.0755 mL	0.3775 mL	0.7550 mL	1.8875 mL
	20 mM	0.0566 mL	0.2831 mL	0.5663 mL	1.4156 mL
	25 mM	0.0453 mL	0.2265 mL	0.4530 mL	1.1325 mL
	30 mM	0.0378 mL	0.1888 mL	0.3775 mL	0.9438 mL
	40 mM	0.0283 mL	0.1416 mL	0.2831 mL	0.7078 mL
	50 mM	0.0227 mL	0.1133 mL	0.2265 mL	0.5663 mL
	60 mM	0.0189 mL	0.0944 mL	0.1888 mL	0.4719 mL
	80 mM	0.0142 mL	0.0708 mL	0.1416 mL	0.3539 mL
	100 mM	0.0113 mL	0.0566 mL	0.1133 mL	0.2831 mL

Velpatasvir Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Velpatasvir1377049-84-7GS-5816GS5816GS 5816HCVSARS-CoVHepatitis C virusSARS coronavirusliver fibrosisinfectionInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Velpatasvir (Synonyms: GS-5816)

Customer Review

Other Forms of Velpatasvir:

Velpatasvir Related Antibodies

10 Publications Citing Use of MCE Velpatasvir

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Velpatasvir Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report